- call +1-201-465-4211
- email sales@mrinsights.biz
Human embryonic stem cell research has emerged as an important
platform for the understanding and treatment of pediatric diseases.
From its inception, however, it has raised ethical concerns based
not on the use of stem cells themselves but on objections to the source
of the cells—specifically, the destruction of preimplantation human
embryos. Despite differences in public opinion on this issue, a large
majority of the public supports continued research using embryonic
stem cells.
Scope of the Report:
This report studies the Human Embryonic Stem Cell (hESC) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Embryonic Stem Cell (hESC) market by product type and applications/end industries.
Maintenance of developmental potential for contribution of derivatives of all three germ layers is an important feature of these cells. This ability remains consistent even after clonal derivation or prolonged undifferentiated proliferation, thus pronouncing its accelerated uptake.
In addition, these are capable in expressing high level of alkaline phosphatase, key transcription factors, and telomerase. These factors are found to be of great importance in the maintenance of the inner cellular mass pluripotency.
The global Human Embryonic Stem Cell (hESC) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Embryonic Stem Cell (hESC).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Astellas Institute of Regenerative Medicine (US)
Asterias Biotherapeutics, Inc. (US)
BD Biosciences (US)
Cell Cure Neurosciences Ltd. (Israel)
Cellular Dynamics International (US)
GE Healthcare (UK)
MilliporeSigma (US)
PerkinElmer, Inc. (US)
Reliance Life Sciences Ltd. (India)
Research & Diagnostics Systems, Inc. (US)
SABiosciences Corp. (US)
STEMCELL Technologies, Inc. (Canada)
Stemina Biomarker Discovery, Inc. (US)
Takara Bio, Inc. (Japan)
TATAA Biocenter AB (Sweden)
Thermo Fisher Scientific, Inc. (US)
UK Stem Cell Bank (UK)
ViaCyte, Inc. (US)
Vitrolife AB (Sweden)
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Totipotent Stem Cell
Pluripotent Stem Cell
Unipotent Stem Cell
Market Segment by Applications, can be divided into
Research
Clinical Trials
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Human Embryonic Stem Cell (hESC) Market Overview
1.1 Product Overview and Scope of Human Embryonic Stem Cell (hESC)
1.2 Classification of Human Embryonic Stem Cell (hESC) by Types
1.2.1 Global Human Embryonic Stem Cell (hESC) Revenue Comparison by Types (2017-2023)
1.2.2 Global Human Embryonic Stem Cell (hESC) Revenue Market Share by Types in 2017
1.2.3 Totipotent Stem Cell
1.2.4 Pluripotent Stem Cell
1.2.5 Unipotent Stem Cell
1.3 Global Human Embryonic Stem Cell (hESC) Market by Application
1.3.1 Global Human Embryonic Stem Cell (hESC) Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Research
1.3.3 Clinical Trials
1.3.4 Others
1.4 Global Human Embryonic Stem Cell (hESC) Market by Regions
1.4.1 Global Human Embryonic Stem Cell (hESC) Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Human Embryonic Stem Cell (hESC) Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Embryonic Stem Cell (hESC) Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Embryonic Stem Cell (hESC) Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Human Embryonic Stem Cell (hESC) Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Embryonic Stem Cell (hESC) Status and Prospect (2013-2023)
1.5 Global Market Size of Human Embryonic Stem Cell (hESC) (2013-2023)
2 Manufacturers Profiles
2.1 Astellas Institute of Regenerative Medicine (US)
2.1.1 Business Overview
2.1.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Institute of Regenerative Medicine (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.2 Asterias Biotherapeutics, Inc. (US)
2.2.1 Business Overview
2.2.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Asterias Biotherapeutics, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.3 BD Biosciences (US)
2.3.1 Business Overview
2.3.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 BD Biosciences (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.4 Cell Cure Neurosciences Ltd. (Israel)
2.4.1 Business Overview
2.4.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Cell Cure Neurosciences Ltd. (Israel) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.5 Cellular Dynamics International (US)
2.5.1 Business Overview
2.5.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Cellular Dynamics International (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.6 GE Healthcare (UK)
2.6.1 Business Overview
2.6.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GE Healthcare (UK) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.7 MilliporeSigma (US)
2.7.1 Business Overview
2.7.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 MilliporeSigma (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.8 PerkinElmer, Inc. (US)
2.8.1 Business Overview
2.8.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 PerkinElmer, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.9 Reliance Life Sciences Ltd. (India)
2.9.1 Business Overview
2.9.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Reliance Life Sciences Ltd. (India) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.10 Research & Diagnostics Systems, Inc. (US)
2.10.1 Business Overview
2.10.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Research & Diagnostics Systems, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.11 SABiosciences Corp. (US)
2.11.1 Business Overview
2.11.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 SABiosciences Corp. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.12 STEMCELL Technologies, Inc. (Canada)
2.12.1 Business Overview
2.12.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 STEMCELL Technologies, Inc. (Canada) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.13 Stemina Biomarker Discovery, Inc. (US)
2.13.1 Business Overview
2.13.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Stemina Biomarker Discovery, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.14 Takara Bio, Inc. (Japan)
2.14.1 Business Overview
2.14.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Takara Bio, Inc. (Japan) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.15 TATAA Biocenter AB (Sweden)
2.15.1 Business Overview
2.15.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 TATAA Biocenter AB (Sweden) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.16 Thermo Fisher Scientific, Inc. (US)
2.16.1 Business Overview
2.16.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Thermo Fisher Scientific, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.17 UK Stem Cell Bank (UK)
2.17.1 Business Overview
2.17.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 UK Stem Cell Bank (UK) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.18 ViaCyte, Inc. (US)
2.18.1 Business Overview
2.18.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 ViaCyte, Inc. (US) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
2.19 Vitrolife AB (Sweden)
2.19.1 Business Overview
2.19.2 Human Embryonic Stem Cell (hESC) Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Vitrolife AB (Sweden) Human Embryonic Stem Cell (hESC) Revenue, Gross Margin and Market Share (2016-2017)
3 Global Human Embryonic Stem Cell (hESC) Market Competition, by Players
3.1 Global Human Embryonic Stem Cell (hESC) Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Human Embryonic Stem Cell (hESC) Players Market Share
3.2.2 Top 10 Human Embryonic Stem Cell (hESC) Players Market Share
3.3 Market Competition Trend
4 Global Human Embryonic Stem Cell (hESC) Market Size by Regions
4.1 Global Human Embryonic Stem Cell (hESC) Revenue and Market Share by Regions
4.2 North America Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
4.3 Europe Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
4.5 South America Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
5 North America Human Embryonic Stem Cell (hESC) Revenue by Countries
5.1 North America Human Embryonic Stem Cell (hESC) Revenue by Countries (2013-2018)
5.2 USA Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
5.3 Canada Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
5.4 Mexico Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
6 Europe Human Embryonic Stem Cell (hESC) Revenue by Countries
6.1 Europe Human Embryonic Stem Cell (hESC) Revenue by Countries (2013-2018)
6.2 Germany Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
6.3 UK Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
6.4 France Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
6.5 Russia Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
6.6 Italy Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Human Embryonic Stem Cell (hESC) Revenue by Countries
7.1 Asia-Pacific Human Embryonic Stem Cell (hESC) Revenue by Countries (2013-2018)
7.2 China Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
7.3 Japan Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
7.4 Korea Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
7.5 India Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
8 South America Human Embryonic Stem Cell (hESC) Revenue by Countries
8.1 South America Human Embryonic Stem Cell (hESC) Revenue by Countries (2013-2018)
8.2 Brazil Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
8.3 Argentina Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
8.4 Colombia Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Human Embryonic Stem Cell (hESC) by Countries
9.1 Middle East and Africa Human Embryonic Stem Cell (hESC) Revenue by Countries (2013-2018)
9.2 Saudi Arabia Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
9.3 UAE Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
9.4 Egypt Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
9.5 Nigeria Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
9.6 South Africa Human Embryonic Stem Cell (hESC) Revenue and Growth Rate (2013-2018)
10 Global Human Embryonic Stem Cell (hESC) Market Segment by Type
10.1 Global Human Embryonic Stem Cell (hESC) Revenue and Market Share by Type (2013-2018)
10.2 Global Human Embryonic Stem Cell (hESC) Market Forecast by Type (2018-2023)
10.3 Totipotent Stem Cell Revenue Growth Rate (2013-2023)
10.4 Pluripotent Stem Cell Revenue Growth Rate (2013-2023)
10.5 Unipotent Stem Cell Revenue Growth Rate (2013-2023)
11 Global Human Embryonic Stem Cell (hESC) Market Segment by Application
11.1 Global Human Embryonic Stem Cell (hESC) Revenue Market Share by Application (2013-2018)
11.2 Human Embryonic Stem Cell (hESC) Market Forecast by Application (2018-2023)
11.3 Research Revenue Growth (2013-2018)
11.4 Clinical Trials Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global Human Embryonic Stem Cell (hESC) Market Size Forecast (2018-2023)
12.1 Global Human Embryonic Stem Cell (hESC) Market Size Forecast (2018-2023)
12.2 Global Human Embryonic Stem Cell (hESC) Market Forecast by Regions (2018-2023)
12.3 North America Human Embryonic Stem Cell (hESC) Revenue Market Forecast (2018-2023)
12.4 Europe Human Embryonic Stem Cell (hESC) Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Human Embryonic Stem Cell (hESC) Revenue Market Forecast (2018-2023)
12.6 South America Human Embryonic Stem Cell (hESC) Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Human Embryonic Stem Cell (hESC) Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Human Embryonic Stem Cell (hESC) Picture
Table Product Specifications of Human Embryonic Stem Cell (hESC)
Table Global Human Embryonic Stem Cell (hESC) and Revenue (
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
